Potent, selective and competitive non-peptide endothelin ETA
receptor antagonist (Ki
= 48 nM). Displays > 1000-fold selectivity over ETB
receptors. Inhibits ET-1-induced pressor response following oral or intravenous administration in vivo
. Inhibits ET-1-induced longitudinal muscle contraction in the mouse colon in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of Bristol-Myers Squibb Company, subject to U.S. Patent No. 5,378,715 and other US and foreign patents
Pharmacological characterization of endothelin receptors-mediated contraction in the mouse isolated proximal and distal colon.
Khan et al.
BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
Webb et al.
The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoazolyl)-1-naphthalenesulfonamide.
Stein et al.
The citations listed below are publications that use Tocris products. Selected citations for BMS 182874 hydrochloride include:
Showing Results 1 - 2 of 2